Our News & Resources

The Memo: YoungHeartValve Building a Truly Durable, Anticoagulation-Free TAVR

Under the direction of Co-Founder and CTO Lakshmi (Prasad) Dasi, PhD, YoungHeartValve is developing a fully synthetic, polymer-based transcatheter aortic valve designed to deliver lifelong durability without the need for chronic anticoagulation.

March 9, 2026

Significant additional funding secured for further development

This unique trans-catheter valve technology features novel, molecular-level, engineered polymeric leaflets with natural biomolecules, making it durable and highly hydrophilic with proven resistance to blood

October 25, 2024

Young Heart Valve Awarded Funding Through SBIR Phase 1

YoungHeartValve has received $2.8 million in additional Small Business Innovation Research (SBIR) grant funding from the National Institutes of Health (NIH) to further advance development

July 25, 2023

Our News & Resources

The Memo: YoungHeartValve Building a Truly Durable, Anticoagulation-Free TAVR

Significant additional funding secured for further development

Young Heart Valve Awarded Funding Through SBIR Phase 1

Categories